pioneer 3 semaglutide Efficacy and safety of oral vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: 12, a double-blind, Phase IIIa, randomised trial | Diabetologia Lesson: Oral Semaglutide: A New

Some reactions demand cold compresses

Generic drugs require FDA approval by demonstrating bio-equivalence to a brand-name drug

As clinicians increasingly encounter patients with IBD as well as obesity, diabetes, or metabolic liver disease, there is a clear need to synthesize what is known about safety, metabolic effects, and IBD-specific outcomes to support evidence-informed clinical decision-making, explains senior investigator and study author Jolle St-Pierre, MD, PhD, FRCPC, a clinical assistant professor in the Division of Gastroenterology and Hepatology at the University of Calgary, Canada, in an email to Gastro Today

Notably, the FLOW trial examined only patients with type 2 diabetes and presumed diabetic kidney disease